Kyowa Kirin KYKOF Stock
Kyowa Kirin Price Chart
Kyowa Kirin KYKOF Financial and Trading Overview
Kyowa Kirin stock price | 14.75 USD |
Previous Close | 16.54 USD |
Open | 16.53 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 16.54 - 16.54 USD |
52 Week Range | 16.06 - 22.85 USD |
Volume | 1.35K USD |
Avg. Volume | 737 USD |
Market Cap | 9.05B USD |
Beta (5Y Monthly) | 0.218 |
PE Ratio (TTM) | 22.353783 |
EPS (TTM) | 0.76 USD |
Forward Dividend & Yield | 0.41 (2.46%) |
Ex-Dividend Date | December 28, 2023 |
1y Target Est | N/A |
KYKOF Valuation Measures
Enterprise Value | -374220062720 USD |
Trailing P/E | 22.353783 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.02150844 |
Price/Book (mrq) | 0.010950084 |
Enterprise Value/Revenue | -0.89 |
Enterprise Value/EBITDA | -3.569 |
Trading Information
Kyowa Kirin Stock Price History
Beta (5Y Monthly) | 0.218 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 22.85 USD |
52 Week Low | 16.06 USD |
50-Day Moving Average | 17.22 USD |
200-Day Moving Average | 19.21 USD |
KYKOF Share Statistics
Avg. Volume (3 month) | 737 USD |
Avg. Daily Volume (10-Days) | 450 USD |
Shares Outstanding | 537.61M |
Float | 248.56M |
Short Ratio | N/A |
% Held by Insiders | 53.66% |
% Held by Institutions | 20.62% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 27 |
Trailing Annual Dividend Yield | 163.22% |
5 Year Average Dividend Yield | 154.00% |
Payout Ratio | 0.50130004 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | September 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 13.76% |
Operating Margin (ttm) | 33.81% |
Gross Margin | 76.28% |
EBITDA Margin | 24.92% |
Management Effectiveness
Return on Assets (ttm) | 5.47% |
Return on Equity (ttm) | 7.35% |
Income Statement
Revenue (ttm) | 420.65B USD |
Revenue Per Share (ttm) | 782.54 USD |
Quarterly Revenue Growth (yoy) | 8.50% |
Gross Profit (ttm) | 311.46B USD |
EBITDA | 104.87B USD |
Net Income Avi to Common (ttm) | 57.91B USD |
Diluted EPS (ttm) | 0.74 |
Quarterly Earnings Growth (yoy) | 124.79% |
Balance Sheet
Total Cash (mrq) | 383.11B USD |
Total Cash Per Share (mrq) | 712.63 USD |
Total Debt (mrq) | 0 USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 4.384 |
Book Value Per Share (mrq) | 1510.655 |
Cash Flow Statement
Operating Cash Flow (ttm) | 97.41B USD |
Levered Free Cash Flow (ttm) | 54.89B USD |
Profile of Kyowa Kirin
Country | United States |
State | N/A |
City | Tokyo |
Address | Otemachi Financial City Grand Cube |
ZIP | 100-0004 |
Phone | 81 3 5205 7200 |
Website | https://www.kyowakirin.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 5982 |
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Q&A For Kyowa Kirin Stock
What is a current KYKOF stock price?
Kyowa Kirin KYKOF stock price today per share is 14.75 USD.
How to purchase Kyowa Kirin stock?
You can buy KYKOF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kyowa Kirin?
The stock symbol or ticker of Kyowa Kirin is KYKOF.
Which industry does the Kyowa Kirin company belong to?
The Kyowa Kirin industry is Drug Manufacturers-General.
How many shares does Kyowa Kirin have in circulation?
The max supply of Kyowa Kirin shares is 534.69M.
What is Kyowa Kirin Price to Earnings Ratio (PE Ratio)?
Kyowa Kirin PE Ratio is 19.40789400 now.
What was Kyowa Kirin earnings per share over the trailing 12 months (TTM)?
Kyowa Kirin EPS is 0.76 USD over the trailing 12 months.
Which sector does the Kyowa Kirin company belong to?
The Kyowa Kirin sector is Healthcare.